Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and fatal disease.
The average survival time has a range between 2 to 5 years, but the progression rate and the
size of damage could result unpredictable. This fibrotic illness is limited to lung with low or
absent inflammation. Recently, new therapeutic options have been described. Clinical trials
were not powered to detect statistically significant differences in mortality; but these have
shown a reduction in the rate of decline in lung function. The results remain variables due to
the heterogeneity observed in these patients. The challenge is to discover new predicting
outcomes, biological indicators of disease progression, short-term measures of therapeutic response or predictors
of survival time useful to take decisions about the treatment or help to determine the need of lung transplantation
and contribute to it.
Keywords: Biomarkers, heterogeneity, idiopathic pulmonary fibrosis, myofibroblast, translational
Rights & PermissionsPrintExport